Holen Sie sich die Stockscreener-App
0.6125
0.00%
0.00
Schlusskurs vom Vortag:
$0.6125
Offen:
$0.61
24-Stunden-Volumen:
20,193
Relative Volume:
0.05
Marktkapitalisierung:
$19.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-0.1873
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+0.87%
1M Leistung:
-0.24%
6M Leistung:
+107.63%
1J Leistung:
-78.12%
1-Tages-Spanne:
$0.6001
$0.6398
1-Wochen-Bereich:
$0.59
$0.69
52-Wochen-Spanne:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Vergleichen Sie RLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.95 | 1.26B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.66 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.6173 | 110.24M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1543 | 351.80M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.26 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Best data tools to analyze Relmada Therapeutics Inc. stock2025 Trading Recap & Daily Stock Trend Reports - Newser
Recovery Setup Building in Relmada Therapeutics Inc. Experts SayQuarterly Market Review & Community Shared Stock Ideas - beatles.ru
Tools to assess Relmada Therapeutics Inc.’s risk profileTrade Risk Report & Capital Efficiency Focused Ideas - Newser
Is Relmada Therapeutics Inc. a candidate for recovery playTrade Analysis Report & Reliable Entry Point Trade Alerts - Newser
Statistical indicators supporting Relmada Therapeutics Inc.’s strengthPortfolio Value Report & Weekly Hot Stock Watchlists - Newser
Market reaction to Relmada Therapeutics Inc.’s recent news2025 Big Picture & Breakout Confirmation Trade Signals - Newser
Advanced analytics toolkit walkthrough for Relmada Therapeutics Inc.July 2025 Snapshot & Smart Allocation Stock Tips - Newser
How to integrate Relmada Therapeutics Inc. into portfolio analysis toolsEarnings Summary Report & Weekly Top Gainers Alerts - Newser
Will Relmada Therapeutics Inc. price bounce be sustainable2025 Biggest Moves & Precise Buy Zone Identification - Newser
Evaluating Relmada Therapeutics Inc. with trendline analysisJuly 2025 Highlights & Verified Short-Term Plans - Newser
What data driven models say about Relmada Therapeutics Inc.’s futureJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Order flow analysis tools used on Relmada Therapeutics Inc.Trade Ideas & Risk Managed Investment Entry Signals - Newser
Using fundamentals and technicals on Relmada Therapeutics Inc.2025 Analyst Calls & AI Driven Price Predictions - Newser
Is it time to cut losses on Relmada Therapeutics Inc.Earnings Overview Summary & Consistent Return Strategy Ideas - Newser
Is This the Dip to Buy in Relmada Therapeutics Inc.July 2025 Patterns & Fast Moving Market Watchlists - newsimpact.co.kr
When is the best time to exit Relmada Therapeutics Inc.2025 Fundamental Recap & Real-Time Market Sentiment Alerts - Newser
Will Relmada Therapeutics Inc. benefit from macro trends2025 Stock Rankings & High Yield Equity Trading Tips - Newser
Is Relmada Therapeutics Inc. forming a bullish divergenceSwing Trade & Free Real-Time Volume Trigger Notifications - sundaytimes.kr
What’s next for Relmada Therapeutics Inc. stock pricePortfolio Risk Report & Weekly High Potential Stock Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Positive Momentum - MSN
Is a relief rally coming for Relmada Therapeutics Inc. holdersJuly 2025 Price Swings & Verified Trade Idea Suggestions - Newser
Why Relmada Therapeutics Inc. stock attracts strong analyst attention2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
What makes Relmada Therapeutics Inc. stock price move sharplyJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Building trade automation scripts for Relmada Therapeutics Inc.Weekly Loss Report & Long-Term Capital Growth Strategies - Newser
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call Transcript - MSN
Relmada taking steps to launch clinical trial of sepranolone in PWS - Prader-Willi Syndrome News
Relmada Therapeutics Reports Positive Momentum in Q2 Earnings Call - AInvest
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relmada Therapeutics Inc-Aktie (RLMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 11 '24 |
Buy |
2.99 |
51,407 |
153,707 |
384,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
0.88%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):